What’s new at SeqOne?
New platform features, customer success stories, awards and other great news about SeqOne…. you’ll find it all here. Journalists, we have a dedicated page for you.
-
News18 January 2021
Using molecular clocks to tell cancer time
We all know tracking metastatic cancer progression is vital for ongoing monitoring of cancer patients, but how do metastatic cancers arise in the first place? [...]
-
Platform features3 December 2020
Detect fusion genes with SeqOne!
https://youtu.be/eYfj7JlKc4k RNAseq analysis is now possible using the SeqOne Platform so that you can include the detection of expressed SNVs, Indels and fusion genes in [...]
-
Platform features14 May 2020
Mobile element insertion (MEI) detection for NGS based clinical diagnostics
A growing number of scientific articles describe the pathogenic role of MEI’s, bringing a renewed focus on their importance in clinical diagnosis. Although NGS makes [...]
-
News Press release1 May 2020
A French start-up harnesses the power of the latest generation genomic sequencers to dramatically increase COVID 19 testing capacity
SeqOne Genomics, a start-up specialized in genomic analysis software, is partnering with leading medical testing labs to develop an approach that delivers up to 100 [...]
- News Press release
1 May 2020
Tests du Covid-19 : une startup française s’allie avec les leaders industriels pour contribuer à l’augmentation massive de la capacité nationale de dépistage
Un dépistage massif et précis est l’une des armes incontournables dans la lutte contre le Covid-19. Tous les experts s’accordent en effet sur l’urgence et l’absolue nécessité [...]
-
Platform features31 March 2020
Challenges and importance of mid-sized deletion identification for genomic medicine
The clinical importance of mid-sized deletions is becoming increasingly apparent with a growing number of variants of this type being identified as pathogenic in the [...]
-
News Press release30 January 2020
EUROFINS BIOMNIS AND SEQONE PARTNER TO IMPROVE CLINICAL ACCESS TO WHOLE EXOME TESTING
Eighty percent of rare diseases are genetic in origin and result from a small number of genetic mutations. Identifying these variations is essential in diagnosing [...]
- News Press release
23 January 2020
EUROFINS BIOMNIS ET SEQONE S’ASSOCIENT POUR OPTIMISER L’INTERPRÉTATION DES DONNÉES DU SÉQUENÇAGE DE L’EXOME
80% des maladies rares sont d’origine génétique et résultent de la mutation d’un seul gène majeur ou d’une combinaison de mutations génétiques. L’identification de ces [...]
-
BioTech15 October 2019
SeqOne nommée startup de l’année 2019 en Occitanie par Ernst & Young
SeqOne a été nommée startup de l’année pour l’édition 2019 du prix de l’”Entrepreneur de l’année” région Occitanie, proposé par Ernst & Young. Prochaine étape [...]
-
News28 March 2019
SeqOne raises €3m to accelerate the adoption of genetic testing in healthcare
SeqOne announces a three million euro funding round led by Elaia with IRDI / SORIDEC and supported by BPI France. The funding will accelerate the [...]
- News
28 March 2019
SeqOne lève €3m euros pour mettre les tests génomiques au service du diagnostic et de la médecine personnalisée
Montpellier, le 28 mars 2019 La start-up montpelliéraine de bioinformatique SeqOne annonce une levée de fonds de 3 millions d’euros mené par Elaia avec la [...]
-
BioTech News28 February 2018
Canadian and French startups announce genomics partnership to better diagnose rare disease
February 28th, 2018: Paris, France & Toronto, Canada Gene42 Inc., a Toronto company that develops software for precision medicine, and SeqOne, a French life [...]